Cigna GroupCI
Cigna Group Financial Overview 2021–2025
Updated Jul 10, 2026After absorbing a substantial equity write-down in the prior year, The Cigna Group rebounded to deliver a 73% surge in shareholders' net income to $5.96 billion in FY2025. This dramatic swing underscores a highly deliberate corporate pivot: the company is systematically shedding its traditional medical risk portfolio to double down on its highly profitable pharmacy and specialty care engine.
This transformation is anchored by the Evernorth Health Services segment, where adjusted revenue climbed from $131.9 billion in FY2021 to a massive $235 billion in FY2025. To fund this expansion and consolidate focus, management aggressively optimized the corporate umbrella. In March 2025, the company finalized the sale of its Medicare Advantage operations to HCSC for $4.9 billion in cash. While this divestiture intentionally shrank total medical customers by 5%, underlying business strength still allowed overall adjusted income from operations to rise 4% to $8.01 billion for the year.
The company simultaneously executed a disciplined capital return strategy, highlighted by $7.0 billion in stock repurchases during FY2024. By the close of FY2025, the market valued the leaner, services-focused enterprise at a $72.5 billion market cap. Shares ended the year at $275.23, trading at a conservative 12.4x earnings multiple on $22.18 in earnings per share.
Recent Developments (Q4 2025 and Q1 2026)
Cigna entered Q1 2026 with a major leadership transition. Brian C. Evanko will succeed David M. Cordani as Chief Executive Officer on July 1, 2026. First-quarter total revenues grew 5% year-over-year to $68.5 billion, driving a 25% increase in net income to $1.65 billion. The Evernorth segment led this expansion, posting a 9% jump in adjusted revenues.
Bulls argue the strategic pivot is paying off, as Cigna Healthcare achieved an 18% increase in pre-tax adjusted income, highlighting robust margin expansion. Conversely, bears warn the 21% drop in Cigna Healthcare adjusted revenues during Q1 2026 pressures the enterprise to maintain aggressive Evernorth growth to offset top-line shrinkage. The stock traded at 13.1x earnings as of April 30, 2026.
What to watch: the CEO transition on July 1, 2026; realization of $500 million in targeted savings from the new rebate-free pharmacy model.
Rev
$274.90B
FY2025
NI
$6.29B
FY2025
EPS
$22.33
FY2025
OCF
$9.60B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
All CI Financial Metrics(57)
Income Statement
Balance Sheet
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Short-Term Investments
- Inventory
- Prepaid & Other
- PP&E
- Goodwill
- Intangibles
- Other Non-current
- Total Liabilities
- Current Liabilities
- Accounts Payable
- Short-Term Debt
- Long-Term Debt
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- APIC
- Treasury Stock
- NCI
- Total L&E
- Shares Outstanding
Cash Flow
Recent SEC Filings
Cigna Group 8-K Report, Financial Results (Jul 30, 2026)
The Cigna Group (CI) filed an 8-K on July 30, 2026, to report its financial results for the three months ended June 30, 2026. While the 8-K itself is brief and primarily serves to incorporate by reference a press release containing the detailed financial information, this filing signals a key update for investors on the company's operational and financial performance for the second quarter of 2026. Investors should refer to the furnished press release (Exhibit 99.1) for substantive details regarding revenue, earnings, segment performance, and any forward-looking guidance. This filing is a standard procedural step to make those results publicly available and officially part of the company's disclosures, although the press release itself is not deemed 'filed' under Section 18 of the Exchange Act unless specifically incorporated into other filings.
Cigna Group 8-K Report, Regulation FD Disclosure (May 13, 2026)
The Cigna Group (CI) has issued an 8-K filing on May 13, 2026, to reaffirm its previously issued full-year 2026 outlook. During upcoming investor meetings, company officials expect to confirm their projected consolidated adjusted income from operations on a per-share basis of at least $30.35. This affirmation signals management's confidence in the company's ongoing performance and its ability to meet financial targets for the year. The filing also provides a definition of consolidated adjusted income from operations, a key non-GAAP metric used by management to assess underlying business performance. While the company is unable to provide a GAAP reconciliation for this forward-looking metric due to the unpredictable nature of certain components like investment gains/losses and special items, investors should note that this measure is distinct from GAAP shareholders' net income. The reaffirmation of guidance is a significant data point for investors as they evaluate The Cigna Group's financial trajectory and operational stability.
Cigna Group 8-K Report, Financial Results (Apr 30, 2026)
The Cigna Group (CI) has filed an 8-K on April 30, 2026, to report on its financial results for the first quarter ended March 31, 2026. While the filing itself is brief, it incorporates by reference a press release (Exhibit 99.1) which contains the detailed financial performance data and operational highlights for the period. Investors should refer to this press release for specific figures on revenue, earnings, and other key performance indicators. The company has provided this information to comply with disclosure requirements and to keep the market informed of its latest financial standing.
Cigna Group 8-K Report, Shareholder Vote Results (Apr 27, 2026)
Cigna Group (CI) filed an 8-K on April 27, 2026, reporting the outcomes of its Annual Meeting of Shareholders held on April 22, 2026. The meeting saw a strong turnout, with approximately 90% of outstanding shares represented. Key outcomes include the overwhelming approval of the twelve director nominees for one-year terms, indicating shareholder confidence in the current board leadership. Additionally, shareholders provided advisory approval for the company's executive compensation plan and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2026, both by significant margins. However, a shareholder proposal concerning the right to act by written consent narrowly failed to gain majority support. This proposal received more votes against than for, suggesting a divergence of opinion on this specific governance matter. Overall, the results reflect strong shareholder support for the company's leadership and financial oversight, while also highlighting a debate around certain corporate governance aspects.
Cigna Group 8-K Report, Executive Changes (Mar 3, 2026)
The Cigna Group announced a significant leadership transition through an 8-K filing on March 3, 2026. Effective July 1, 2026, Brian C. Evanko will assume the role of Chief Executive Officer, succeeding David M. Cordani, who will transition to Executive Chair of the Board. This move signifies an internal promotion for Mr. Evanko, who has held various senior leadership positions within the company, including President and Chief Operating Officer. The filing also detailed Mr. Evanko's new compensation package, which includes a base salary of $1.3 million, an Enterprise Incentive Plan target of $2.6 million, and a Long-Term Incentive target of $15.1 million, along with a one-time transitional equity award. In addition to the CEO succession, Cigna Group reaffirmed its full-year 2026 financial outlook, projecting consolidated adjusted income from operations of at least $30.25 per share. The company also reiterated specific outlooks for its Evernorth and Cigna Healthcare segments. The filing also noted board composition changes, including Mr. Evanko's election to the Board and Mr. Eric J. Foss's appointment as Lead Independent Director, effective April 1, 2026.
View all 8-K filings →